BRK-B vs MRSH
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The deterministic health profile is weak, highlighted by a Piotroski F-Score of 3/9, indicating deteriorating operational efficiency and profitability trends. While the company maintains a fortress balance sheet with a Debt/Equity ratio of 0.19 and a Current Ratio of 7.07, the stock is trading at a significant premium to its growth-based intrinsic value of $217.21. Negative YoY revenue and earnings growth, coupled with a bearish technical trend, offset the positive analyst sentiment and long-term historical performance.
MRSH demonstrates stable operational health with a Piotroski F-Score of 6/9 and a strong ROE of 27.57%, yet it trades at a massive premium to its Graham Number ($73.7) and Intrinsic Value ($55.93). While the company has an exceptional 25-quarter track record of beating earnings estimates, recent YoY earnings growth has contracted by 15.4%. Bearish insider activity, specifically from the CEO, and a 0/100 technical trend suggest significant short-term headwinds despite a 'Buy' analyst consensus. The stock is a high-quality business currently suffering from a valuation disconnect and decelerating earnings momentum.
Compare Another Pair
Related Comparisons
BRK-B vs MRSH: Head-to-Head Comparison
This page compares Berkshire Hathaway Inc. (BRK-B) and Marsh & McLennan Companies, Inc. (MRSH) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.